PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10421491-11	1999	The target of promotion of axonopathies is thought to be similar or linked to NTE which is defined as the phenyl valerate esterase activity (PVE) in nervous tissues resistant to paraoxon and sensitive to mipafox (40 and 50 microM, pH 8.0, 20 min, respectively).	Paraoxon	178-186	patatin like phospholipase domain containing 6	Homo sapiens	78-81	
17663017-1	2007	Brain neuropathy target esterase (NTE), associated with organophosphorus (OP)-induced delayed neuropathy, has the same OP inhibitor sensitivity and specificity profiles assayed in the classical way (paraoxon-resistant, mipafox-sensitive hydrolysis of phenyl valerate) or with lysophosphatidylcholine (LysoPC) as the substrate.	Paraoxon	199-207	patatin like phospholipase domain containing 6	Homo sapiens	6-32	
17663017-1	2007	Brain neuropathy target esterase (NTE), associated with organophosphorus (OP)-induced delayed neuropathy, has the same OP inhibitor sensitivity and specificity profiles assayed in the classical way (paraoxon-resistant, mipafox-sensitive hydrolysis of phenyl valerate) or with lysophosphatidylcholine (LysoPC) as the substrate.	Paraoxon	199-207	patatin like phospholipase domain containing 6	Homo sapiens	34-37	
10720708-5	2000	NTE is defined as the activity resistant to paraoxon (40 microM) and sensitive to mipafox (50 microM).	Paraoxon	44-52	patatin like phospholipase domain containing 6	Homo sapiens	0-3	
10421491-13	1999	A complete titration curve of paraoxon-resistant PVEs by mipafox (0-1 mM) dissected, besides NTE (I50 about 10 microM), another PVE with an I50 of approximately 200 microM.	Paraoxon	30-38	patatin like phospholipase domain containing 6	Homo sapiens	93-96	
10421492-4	1999	Following the same operational criteria in the soluble fraction of sciatic nerve a paraoxon-resistant but mipafox-sensitive PVase activity was described and termed as S-NTE, with an apparent lower sensitivity to some inhibitors than particulate NTE.	Paraoxon	83-91	patatin like phospholipase domain containing 6	Homo sapiens	169-172	
10421492-9	1999	Under this improved sequential paraoxon/mipafox inhibition procedure S-NTE represents about 50% of total PVases while in the usual concurrent assay it was only apparently about 1-2%.	Paraoxon	31-39	patatin like phospholipase domain containing 6	Homo sapiens	71-74	
8568835-2	1995	NTE is operationally defined in this article as the phenylvalerate esterase activity which is resistant to inhibition by 40 microM paraoxon and sensitive to 250 microM mipafox.	Paraoxon	131-139	patatin like phospholipase domain containing 6	Homo sapiens	0-3	
9463518-0	1997	Reversible inhibition can profoundly mislead studies on progressive inhibition of enzymes: the interaction of paraoxon with soluble neuropathy target esterase.	Paraoxon	110-118	patatin like phospholipase domain containing 6	Homo sapiens	132-158	
9463518-2	1997	O,O"-diethyl p-nitrophenyl phosphate (paraoxon) was the non-neurotoxic OP of choice for the standard assay of NTE to block the non-relevant esterases (phenylvalerate hydrolases) because it was supposed not to inhibit the enzymic activity of the target protein while N,N"-diisopropyl phosphorodiamidofluoridate (mipafox) is the neuropathic OP used to inhibit (and so to detect) NTE activity.	Paraoxon	38-46	patatin like phospholipase domain containing 6	Homo sapiens	110-113	
9463518-2	1997	O,O"-diethyl p-nitrophenyl phosphate (paraoxon) was the non-neurotoxic OP of choice for the standard assay of NTE to block the non-relevant esterases (phenylvalerate hydrolases) because it was supposed not to inhibit the enzymic activity of the target protein while N,N"-diisopropyl phosphorodiamidofluoridate (mipafox) is the neuropathic OP used to inhibit (and so to detect) NTE activity.	Paraoxon	38-46	patatin like phospholipase domain containing 6	Homo sapiens	377-380	
9463518-6	1997	Our results suggest that paraoxon could produce a strong reversible effect on S-NTE when the concurrent procedure is used so that it interferes with its inhibition by both neuropathy inducers and promoters.	Paraoxon	25-33	patatin like phospholipase domain containing 6	Homo sapiens	78-83	
3190748-6	1988	Among 14 potential substrates NTE hydrolysed phenyl phenoxyacetate and phenyl thiophenoxyacetate faster (1.5-1.7X) than PV, but selectivity of these substrates for NTE among the paraoxon-resistant esterases was only 35-52%.	Paraoxon	178-186	patatin like phospholipase domain containing 6	Homo sapiens	30-33	
4049405-4	1985	We report here that paraoxon is apparently able to reduce the rate of inhibition of both neurotoxic esterase isozymes by mipafox in a concentration-dependent manner.	Paraoxon	20-28	patatin like phospholipase domain containing 6	Homo sapiens	89-108	
2051750-2	1991	NTE activity is calculated from the rate of phenyl valerate hydrolysis resistant to paraoxon and sensitive to mipafox inhibition under specified conditions of inhibitor concentrations, pH, temperature, and incubation times with inhibitors and substrate.	Paraoxon	84-92	patatin like phospholipase domain containing 6	Homo sapiens	0-3